Crossmark

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) following atezolizumab and bevacizumab treatment for hepatocellular carcinoma

Published Online: 2025-12-17

Published Print: 2026-01

Authors

Li, Yi-Xiao https://orcid.org/0000-0001-8159-3546
Wang, Rui-Yun

Hao, Yan-Lei
License Information

Text and Data Mining valid from 2025-12-17

Version of Record valid from 2025-12-17
More Information

Article History

Received: 2 June 2025

Accepted: 16 October 2025

First Online: 17 December 2025

Declarations

:

: No identifiable information was disclosed in writing this case report; further ethical board approval was waived in accordance with local regulations.

: Written consent was obtained from the patient’s family for publishing his medical data for scientific purposes.

: The authors declare no competing interests.

Document is current